Meningococcal polysaccharide vaccine groups B and C Uses, Dosage, Side Effects and more
VA-MENGOC-BC is a meningococcal B and C vaccine and an outer membrane vesicle (OMV)-based vaccine. The OMVs contain over 100 proteins, and are derived from meningococcal group B and capsular polysaccharide of meningococcal group C. As there already exists a polysaccharide-based vaccine against meningococcal disease originating from serogroups A,C,W135, and Y, this vaccine was created for use against serogroups B and C.This vaccine causes induction of bactericidal antibodies with broad cross-reactivity. Novel antigens such as γ-glutamyltranspeptidase, exopolyphosphatase, and a cell-binding factor protein were also identified with administration of this vaccine by a study. This vaccine may also induce moderate protection against N. gonorrhoeae. As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.
| Trade Name | Meningococcal polysaccharide vaccine groups B and C |
| Generic | VA-MENGOC-BC® |
| VA-MENGOC-BC® Other Names | Meningococcal polysaccharide vaccine groups B and C |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
